Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS-Probionorm in Patients with Dysbiosis
NCT06886399Phase 2Completed
- Sponsor
- Industrial Microbiology
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AS-Probionorm in dysbiosis and irritable bowel syndrome (IBS) (3 arms), sponsored by Industrial Microbiology. Primary endpoints: Safety of the study drug at Day 42 and The effectiveness of the drug at 24 hours. Started Jul 2024; status: completed.
02
Drugs
AS-Probionorm
03
Conditions
dysbiosisirritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06886399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886399.